Skip to main content
Premium Trial:

Request an Annual Quote

Theradiag to Commercialize PredictImmune IBD Test in French-Speaking Europe and Africa

NEW YORK – Immune prognostic tools developer PredictImmune announced Monday an exclusive partnership for diagnostic company Theradiag to promote, license, and distribute the PredictSure IBD test in French-speaking countries in Europe and Africa.

France-based Theradiag, which specializes in in vitro diagnostics and theranostics for autoimmune disease, will lead commercialization in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries in northwest Africa.

Other terms of the deal were not disclosed.

The IBD test, which was commercialized in the United Kingdom and Ireland earlier this year, will be PredictImmune's first product launch in continental Europe. The company recently announced a similar partnership with KSL Biomedical for North American commercialization of the IBD test.

The blood-based biomarker test, which leverages quantitative PCR technology, is meant to provide a preview of future disease outcomes at the point of diagnosis, allowing for better treatment choices earlier in the disease, Cambridge, UK-based PredictImmune said in a statement.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.